Compare TRVG & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | ZURA |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.1M | 252.9M |
| IPO Year | N/A | N/A |
| Metric | TRVG | ZURA |
|---|---|---|
| Price | $2.93 | $4.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $3.96 | ★ $11.38 |
| AVG Volume (30 Days) | 56.7K | ★ 369.0K |
| Earning Date | 02-03-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $614,486,683.00 | N/A |
| Revenue This Year | $18.36 | N/A |
| Revenue Next Year | $9.18 | N/A |
| P/E Ratio | $97.46 | ★ N/A |
| Revenue Growth | ★ 14.41 | N/A |
| 52 Week Low | $2.02 | $0.97 |
| 52 Week High | $5.83 | $4.68 |
| Indicator | TRVG | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 63.27 |
| Support Level | $2.82 | $4.20 |
| Resistance Level | $3.15 | $4.45 |
| Average True Range (ATR) | 0.11 | 0.23 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 30.56 | 80.85 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.